- Home
- DHR vs GILD Comparison
DHR vs GILD Comparison
Compare DHR & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHR | GILD |
|---|---|---|
| Founded | 1969 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.7B | 184.4B |
| IPO Year | 2006 | 2001 |
Fundamental Metrics
Financial Performance| Metric | DHR | GILD |
|---|---|---|
| Price | $189.99 | $137.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 18 |
| Target Price | ★ $249.93 | $146.50 |
| AVG Volume (30 Days) | 3.2M | ★ 5.1M |
| Earning Date | 04-21-2026 | 04-23-2026 |
| Dividend Yield | 0.68% | ★ 2.39% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | 5.05 | ★ 6.78 |
| Revenue | $19,893,000,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $5.34 | $4.69 |
| Revenue Next Year | $6.17 | $5.95 |
| P/E Ratio | $37.46 | ★ $20.26 |
| Revenue Growth | 8.53 | ★ 9.98 |
| 52 Week Low | $171.00 | $95.30 |
| 52 Week High | $242.80 | $157.29 |
Technical Indicators
Market Signals| Indicator | DHR | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 34.25 | 36.61 |
| Support Level | $185.93 | $108.90 |
| Resistance Level | $206.93 | $149.38 |
| Average True Range (ATR) | 4.45 | 3.11 |
| MACD | 0.28 | -1.41 |
| Stochastic Oscillator | 24.37 | 8.96 |
Price Performance
Historical ComparisonAbout DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).